DSGN
Design Therapeutics Inc
NASDAQ: DSGN · HEALTHCARE · BIOTECHNOLOGY
$13.41
+1.82% today
Updated 2026-05-05
Market cap
$822.56M
P/E ratio
—
P/S ratio
29,402.82x
EPS (TTM)
$-1.19
Dividend yield
—
52W range
$3 – $17
Volume
0.4M
Design Therapeutics Inc (DSGN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $834000.00 | $226.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -100.0% | -100.0% | — | — | — | — |
| Cost of revenue | $1654.00 | $5000.00 | $129000.00 | $466000.00 | $537000.00 | $596000.00 | $622000.00 |
| Gross profit | $-820.00 | $-5000.00 | $-129000.00 | $-466000.00 | $-537000.00 | $-596000.00 | $-622000.00 |
| Gross margin | -0.1% | -2212.4% | — | — | — | — | — |
| R&D | $1.65M | $6.06M | $24.78M | $48.61M | $57.06M | $44.35M | $59.13M |
| SG&A | $1.09M | $2.50M | $11.05M | $18.98M | $21.13M | $18.03M | $20.34M |
| Operating income | $-1.91M | $-8.56M | $-35.83M | $-67.59M | $-78.19M | $-62.38M | $-79.47M |
| Operating margin | -228.8% | -3785840.7% | — | — | — | — | — |
| EBITDA | $-1.91M | $-8.28M | $-35.70M | $-67.19M | $-66.33M | $-48.99M | $-78.84M |
| EBITDA margin | -228.8% | -3661504.4% | — | — | — | — | — |
| EBIT | $-1.91M | $-8.28M | $-35.83M | $-67.59M | $-66.86M | $-49.59M | $-79.47M |
| Interest expense | $0.00 | $0.00 | $298000.00 | $4.69M | — | — | — |
| Income tax | $139000.00 | $-201297.00 | $-107558.00 | $-4.69M | $-1.00 | — | — |
| Effective tax rate | -7.3% | 2.4% | 0.3% | 7.4% | 0.0% | 0.0% | 0.0% |
| Net income | $-2.05M | $-8.28M | $-35.53M | $-58.62M | $-66.86M | $-49.59M | $-69.79M |
| Net income growth (YoY) | — | -304.5% | -329.1% | -65.0% | -14.1% | +25.8% | -40.7% |
| Profit margin | -245.4% | -3663716.8% | — | — | — | — | — |